Research programme: extended release opioid analgesics - Ensysce Biosciences

Drug Profile

Research programme: extended release opioid analgesics - Ensysce Biosciences

Alternative Names: ER Morphine - PharmacoFore; ER Morphine Bio-MD™ System; ER Morphine- Ensysce Biosciences; ER Oxymorphone - Ensysce Biosciences; ER Oxymorphone - PharmacoFore; ER Oxymorphone Bio-MD™ System; PF-03; PFR 03088; PFR 03325

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 24 Feb 2016 Preclinical trials in Pain in USA (PO) before February 2016
  • 19 Jan 2016 Signature Therapeutics has merged into Ensysce Biosciences
  • 03 Sep 2012 Extended release opioid analgesics research programme is available for licensing as of 03 Sep 2012. www.signaturerx.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top